Performance and value of IFN-Lambda3 and IFN-Lambda4 genotyping in patients with chronic hepatitis c (CHC) Genotype 2/3 in a real world setting

2Citations
Citations of this article
18Readers
Mendeley users who have this article in their library.

Abstract

Background SNPs near the interferon lambda (IFNL) 3 gene are predictors for sustained virological response (SVR) in patients with chronic hepatitis C genotype (GT) 1. In addition, a dinucleotide frame shift in ss469415590 was described, which generates IFNL4. In this study, we compared the role of IFNL4 variants with IFNL3-(rs12979860) and IFNL3-(rs8099917) on response to pegylated (PEG)-IFN and Ribavirin (RBV) in patients with chronic hepatitis C GT2/3. Methods We recruited 1006 patients with chronic hepatitis C and GT2/3 in a large German registry. A treatment with PEG-IFN and Ribavirin was started by 959 patients. We performed genotyping of IFNL3 (rs12979860, n = 726; rs8099917, n = 687) and of IFNL4 (ss469415590; n = 631). Results Both preferable IFNL3 genotypes were associated with RVR (both p<0.0001) rather than with SVR (rs12979860: p = 0.251; rs8099917: p = 0.447). Only RVR was linked to SVR in univariate and multivariate analyzes (both p<0.001). Concordance of genotyping in patients with available serum samples and EDTA blood samples (n = 259) was more than 96% for both IFNL3 SNPs. IFNL3-(rs12979860) correlated with IFNL4: 99.2% of patients with IFNL3-(rs12979860)-CC were IFNL4-(ss469415590)-TT/TT. IFNL3-(rs12979860)-CT was linked with IFNL4-(ss469415590)-TT/ΔG (98.0%) and IFNL3-(rs12979860)-TT was associated with IFNL4-(ss469415590)-ΔG/ΔG (97.6%). Conclusion IFNL3 genotyping from serum was highly efficient and can be used as an alternative if EDTA whole blood is not available. In Caucasian GT2/3 patients genotyping for INFL4- (ss469415590) does not lead to additional information for the decision-making process. Importantly, IFNL3 SNPs were not associated with SVR but with RVR. Even in the era of new direct acting antiviral (DAA) therapies, IFNL3 testing may therefore still be considered for naïve GT2/3 patients to decide if dual Peg-IFN/RBV therapy is an option in resource limited regions.

References Powered by Scopus

Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis

3558Citations
N/AReaders
Get full text

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

3187Citations
N/AReaders
Get full text

Natural history of liver fibrosis progression in patients with chronic hepatitis C

2875Citations
N/AReaders
Get full text

Cited by Powered by Scopus

A simple PCR-RFLP method for genotyping of IFNL4 rs368234815 polymorphism in patients with chronic hepatitis C

8Citations
N/AReaders
Get full text

Donor IFNL4 genotype is associated with early post-transplant fibrosis in recipients with hepatitis C

5Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Wiegand, S. B., Heidrich, B., Susser, S., Taranta, M. R., Petersen, J., Böker, K. H. W., … Cornberg, M. (2015). Performance and value of IFN-Lambda3 and IFN-Lambda4 genotyping in patients with chronic hepatitis c (CHC) Genotype 2/3 in a real world setting. PLoS ONE, 10(12). https://doi.org/10.1371/journal.pone.0145622

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 8

62%

Researcher 4

31%

Professor / Associate Prof. 1

8%

Readers' Discipline

Tooltip

Medicine and Dentistry 7

58%

Biochemistry, Genetics and Molecular Bi... 3

25%

Agricultural and Biological Sciences 1

8%

Economics, Econometrics and Finance 1

8%

Save time finding and organizing research with Mendeley

Sign up for free